Affiliation:
1. Department of Respiratory and Critical Care Medicine, The Hospital of Nan'an, Quanzhou, China.
Abstract
Rationale:
Radical surgery offers the best chance of cure, it is critical to expand surgery opportunities for patients with early-stage lung cancer to prolong overall survival. However, evidence is still limited regarding the application of neoadjuvant therapy with EGFR-tyrosine kinase.
Patient:
The patient reported here was a 53-year-old woman with right lower lung adenosquamous carcinoma.
Diagnoses:
The lung cancer was staged as T3N1M0. Tumor genotype disclosed EGFR Exon19 c.2235-2249de p.E746-A750del.
Intervention:
After neoadjuvant treatment with icotinib, she underwent thoracotomy and achieved pathological complete response.
Outcomes:
She is currently receiving adjuvant icotinib therapy without recurrence or metastasis during 18-month follow-up.
Lessons:
Our case indicated that the feasibility of neoadjuvant icotinib in EGFR-mutant lung adenosquamous carcinoma.
Publisher
Ovid Technologies (Wolters Kluwer Health)